Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.
Rosell
Rafael
R
Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, Badalona, Barcelona, Spain. rrosell@ns.hugtip.scs.es
Felip
Enriqueta
E
Reguart
Noemí
N
Moran
Teresa
T
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation / Q000235:genetics*
D000970:Antineoplastic Agents; D066246:ErbB Receptors